What we're reading, February 16, 2016: Affordable Care Act enrollment for 2016 is far below initial estimates; healthcare record hacks increased 11,000% in 2015; and genetic testing hasn't seen wide adoption among consumers.
Affordable Care Act enrollment has fallen far short of initial estimates. The final number of people who signed up for health insurance on the state and federal exchanges was 40% lower than earlier estimates, according to USA Today. The final 12.7 million who signed up is also well below the 2010 estimates for 2016 enrollment from RAND and the Congressional Budget Office: 27 million and 21 million, respectively.
Hacks of healthcare records were up 11,000% last year. Of the one-third of Americans whose healthcare records were compromised with criminals gaining access to valuable personal information, most were unaware, reported NBC News. While Social Security numbers go for $15, complete health records go for $60 each because they can be used to order prescriptions and even file false tax returns. And unlike credits cards, healthcare information cannot be canceled.
Despite being marketed to consumers, genetic tests are still not being widely adopted—and doctors are ok with that. STAT reported the results of a poll with the Harvard T.H. Chan School of Public Health, which found that only 50% of Americans have even heard or read about genetic testing. Furthermore, only 6% have undergone genetic testing. A survey of physicians found that a minority had recommended patients get their genome sequenced, which may account for the low uptake among consumers.
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen